The Rheumatologist
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
  • Technology
    • Electronic Health Records
    • Apps
    • Information Technology
  • Resources
    • Issue Archives
    • Events
    • Multimedia
      • Audio
      • Video
    • From the College
    • American College of Rheumatology
    • Rheumatology Research Foundation
    • Arthritis & Rheumatology
    • Arthritis Care & Research
    • Treatment Guidelines
    • Research Reviews
    • Annual Meeting
      • Abstracts
      • Meeting Reports
    • Rheumatology Image Bank
    • ACR ExamRheum
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rheumatologists Air Frustrations with Pharmacy Benefit Managers at Annual Meeting

Rheumatologists Air Frustrations with Pharmacy Benefit Managers at Annual Meeting

January 19, 2018 • By Larry Beresford

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Timothy OLeary / shutterstock.com

Timothy O’Leary / shutterstock.com

SAN DIEGO—Pharmacy benefit managers (PBMs) and their impact on drug prices and access to high-cost medications by the patients rheumatologists treat was a major theme at the 2017 ACR/ARHP Annual Meeting Nov. 3–8. In one session, industry experts tried to clarify the role for prior authorizations and drug formulary policies and explored ways to constructively reshape the relationship between rheumatologists and PBMs for the benefit of patients. But participants also voiced frustrations over PBM-imposed barriers to access for rheumatologic treatments. Lack of transparency on drug pricing policies for the country’s biggest PBMs remains a flashpoint for much of their frustration.

You Might Also Like
  • Kentucky Launches Probe into Drug Overcharges by Pharmacy Benefit Managers
  • U.S. Probes Contracts Between Drugmakers, Pharmacy Benefit Managers
  • Sen. Lisa Murkowski Addresses Rheumatologists During ACR/ARHP Annual Meeting, Tax Reform & More
Explore This Issue
January 2018
Also By This Author
  • How to Improve Rheumatologist-Hospitalist Communication & Access

PBMs are engaged by health plans to manage their drug benefit programs, serving as third-party administrators or brokers between the manufacturer and the retailer. Originally set up to bring prescription drug utilization and costs under control, they have become very good at negotiating discounted rebates from the manufacturer’s list price. But recent industry consolidations and their resulting clout to control pharmacy costs have altered this dynamic.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The PBMs may be keeping a large part of the savings negotiated with manufacturers for themselves. PBMs also play other roles in the healthcare system, some of which may be beneficial to patients. The three biggest companies, controlling about three-quarters of the market, are ExpressScripts, CVS CareMark and OptumRx.

Dr. Worthing

Dr. Worthing

Rheumatologists say PBMs negatively affect patients through the use of prior authorization requirements, spread pricing, step therapy programs that determine which drug the patient must try first, the use of specialty tiers for biologics and other high-cost medications, requiring patients to pay a percentage of the drug cost rather than just a copayment, and non-medical switching. The latter means changing the patient’s covered drug for reasons unrelated to medical appropriateness. ACR opposes non-medical switching and believes that any such medication changes should involve open discussion with the patient and physician.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

All of these practices can have a huge impact on the lives of rheumatology patients. One of the biggest concerns involves the rebates charged to drug manufacturers by the PBMs. “Too often, our patients’ formularies are determined by a rebate system that incentivizes higher prices, with savings that don’t trickle down to the patient. The highest rebate is determined by the following formula: rebate equals list price times percent of rebate times market share,” explained Angus Worthing, MD, FACP, FACR, chair of the ACR’s Government Affairs Committee and a rheumatologist in practice in Washington, D.C. But because contracts between drug manufacturers and PBMs are proprietary and thus hidden from public view, it isn’t clear what’s really going on, he said.

Pages: 1 2 3 | Single Page

Filed Under: Drug Updates, Legislation & Advocacy, Meeting Reports, Pharma Co. News, Professional Topics Tagged With: ACR/ARHP Annual Meeting, Advocacy, drug, pharmacy benefit managers (PBMs)Issue: January 2018

You Might Also Like:
  • Kentucky Launches Probe into Drug Overcharges by Pharmacy Benefit Managers
  • U.S. Probes Contracts Between Drugmakers, Pharmacy Benefit Managers
  • Sen. Lisa Murkowski Addresses Rheumatologists During ACR/ARHP Annual Meeting, Tax Reform & More
  • ATAP Holds Inaugural In-Person Meeting

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR/ARP Annual Meeting

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Annual Meeting site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2019 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.